Compare · EMBC vs MDLN
EMBC vs MDLN
Side-by-side comparison of Embecta Corp. (EMBC) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EMBC and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 131.6x EMBC ($365.5M).
- Over the past year, EMBC is down 55.5% and MDLN is down 11.8% - MDLN leads by 43.7 points.
- MDLN has hit the wire 7 times in the past 4 weeks while EMBC has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 9 for EMBC).
- Company
- Embecta Corp.
- Medline Inc.
- Price
- -
- -
- Market cap
- $365.5M
- $48.08B
- 1M return
- +21.22%
- +11.97%
- 1Y return
- -55.46%
- -11.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 7
- Recent ratings
- 9
- 25
Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Latest EMBC
- Director Morris Milton Mayo sold $36,971 worth of shares (6,293 units at $5.88), decreasing direct ownership by 10% to 53,828 units (SEC Form 4)
- SEC Form 144 filed by Embecta Corp.
- embecta to Participate in Investor Events
- Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.
- President and CEO Kurdikar Devdatt bought $140,937 worth of shares (30,000 units at $4.70), increasing direct ownership by 4% to 804,919 units (SEC Form 4)
- SVP and CFO Elguicze Jacob bought $93,360 worth of shares (20,000 units at $4.67), increasing direct ownership by 7% to 309,139 units (SEC Form 4)
- Pres, Pharm Svc&Prod Mgmt, CLO Mann Jeffrey Z bought $99,800 worth of shares (20,000 units at $4.99), increasing direct ownership by 8% to 262,915 units (SEC Form 4)
- Director Hombach Robert J. bought $223,848 worth of shares (45,000 units at $4.97), increasing direct ownership by 70% to 109,587 units (SEC Form 4)
- Chief Human Resources Officer Casner Jean covered exercise/tax liability with 1,480 shares, decreasing direct ownership by 2% to 85,915 units (SEC Form 4) (for tax liability)
- SEC Form S-8 filed by Embecta Corp.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M